Skip Navigation

Your Environment. Your Health.

Related Publications

  1. Regardt M, Basharat P, Christopher-Stine L, Sarver C, Björn A, Lundberg IE, Wook Song Y, Bingham CO 3rd, Alexanderson H. Patients' Experience of Myositis and Further Validation of a Myositis-specific Patient Reported Outcome Measure - Establishing Core Domains and Expanding Patient Input on Clinical Assessment in Myositis. Report from OMERACT 12. J Rheumatol. 2015 Dec;42(12):2492-5. doi: 10.3899/jrheum.141243. Epub 2015 May 1. [Abstract]
  2. Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, Brochard K, Corona F, Dressler F, Gerloni V, Apaz MT, Bracaglia C, Cespedes-Cruz A, Cimaz R, Couillault G, Joos R, Quartier P, Russo R, Tardieu M, Wulffraat N, Bica B, Dolezalova P, Ferriani V, Flato B, Bernard-Medina AG, Herlin T, Trachana M, Meini A, Allain-Launay E, Pilkington C, Vargova V, Wouters C, Angioloni S, Martini A; Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Paediatric Rheumatology International Trials Organisation (PRINTO).
    Lancet. 2015 Nov 27. pii: S0140-6736(15)01021-1. doi: 10.1016/S0140-6736(15)01021-1. [Epub ahead of print] [Abstract]

  3. Anyanwu CO, Fiorentino DF, Chung L, Dzuong C, Wang Y, Okawa J, Carr K, Propert KJ, Werth VP. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. 2015 Oct;173(4):969-74. doi: 10.1111/bjd.13915. Epub 2015 Aug 11. [Abstract]
  4. Reed AM, Crowson CS, Hein M, de Padilla CL, Olazagasti JM, Aggarwal R, Ascherman DP, Levesque MC, Oddis CV; RIM Study Group. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskelet Disord. 2015 Sep 17;16:257. doi: 10.1186/s12891-015-0710-3.  PMID: 26382217. [Abstract]
  5. Almeida B, Campanilho-Marques R, Arnold K, Pilkington CA, Wedderburn LR, Nistala K; Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated. Juvenile Dermatomyositis Research Group.
    Arthritis Rheumatol. 2015 Sep;67(9):2495-502. doi: 10.1002/art.39200.

  6. Almeida B, Campanilho-Marques R, Arnold K, Pilkington CA, Wedderburn LR, Nistala KJuvenile Dermatomyositis Disease Activity Collaborative Study Group, Analysis of published criteria for Clinically Inactive Disease in a large Juvenile Dermatomyositis cohort shows that skin disease is underestimated. Arthritis Rheum, 2015 May 18. doi: 10.1002/art.39200. [Epub ahead of print] [Abstract]
  7. Sanner H, Sjaastad I, Flatø B, Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford), 2014 Sep 53(9):1578-85. Epub 2014 Sep 1. [Pub Med]
  8. Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA, Analysis of published criteria for Clinically Inactive Disease in a large Juvenile Dermatomyositis cohort shows that skin disease is underestimated. Neurology, 2014 Jul 83(5):426-33. Epub 2014 Jul 29. [Pub Med]
  9. McCann LJ, Arnold K, Pilkington CA, Huber AM, Ravelli A, Beard L, Beresford MW, Wedderburn LR, Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research. Pediatr Rheumatol Online J, 2014 Jul 12:31. Epub 2014 Jul 21. [Pub Med]
  10. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR; CTD-ILD Special Interest Group, Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax, 2014 May 69(5):428-36.. Epub 2014 May 1. [Pub Med]
  11. Alexanderson H, Del Grande M, Bingham CO 3rd, Orbai AM, Sarver C, Clegg-Smith K, Lundberg IE, Song YW, Christopher-Stine L. Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group. J Rheumatol. 2014 Mar;41(3):581-92. doi: 10.3899/jrheum.131247. Epub 2014 Jan 15. Review. [Abstract]
  12. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC; RIM Study Group, Oddis CV, Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol, 2014 Mar 66(3):740-9. Epub 2014 Mar 1. [Pub Med]
  13. Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, Quartier P, Dolezalova P, Penades IC, Ferriani VP, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, Rider LG, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO), The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann rheum Dis, 2013 May 72(5):686-93. doi: 10.1136/annrheumdis-2012-201483. Epub 2013 May. [Pub Med]
  14. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE; RIM Study Group, Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum, 2013 Feb 65(2):314-24. Epub 2013 Feb 1. [Pub Med]
  15. Alexanderson H, Reed AM, Ytterberg SR, The Myositis Activities Profile -- initial validation for assessment of polymyositis/dermatomyositis in the USA. J. Rheumatol, 2012 Nov 39(11):2134-41. doi: 10.3899/jrheum.120504. Epub 2012 Sep 1. [Pub Med]
  16. Goreshi R, Okawa J, Rose M, Feng R, Lee LA, Hansen CB, Bangert CA, Connolly MK, Davis MD, Callen JP, Fett NM, Fakharzadeh SS, Clarke JT, Werth VP, Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dertmatol, 2012 Apr 132(4):1117-24. Epub 2012 Apr 1. [Pub Med]
  17. Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, Quartier P, Dolezalova P, Penades IC, Ferriani VP, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, Rider LG, Martini A, Ruperto N; for the Paediatric Rheumatology International Trials Organisation (PRINTO), The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis, Ann Rheum Dis, 2012 Jun 26 [Epub ahead of print]. [Abstract]

     

  18. Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, Haines K, Hoeltzel MF, Isgro J, Kahn P, Lang B, Lawler P, Shaham B, Schmeling H, Scuccimarri R, Shishov M, Stringer E, Wohrley J, Ilowite NT, Wallace C; Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance, Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference, Arthritis Care Res (Hoboken), 2012 Apr 64(4):546-53. doi 10.1002/acr.20695. [Abstract]

     

  19. Goreshi R, Chock M, Foering K, Feng R, Okawa J, Rose M, Fiorentino D, Werth V, Quality of life in dermatomyositis, J Am Acad Dermatol, 2011 Dec 65(6):1107-16. Epub 2011 Jul 1. [ Pub Med ]

     

  20. Sanner H, Kirkhus E, Merckoll E, Tollisen A, Røisland M, Lie BA, Taraldsrud E, Gran JT, Flatø B, Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study, Arthritis Care Res (Hoboken), 2010 Aug 62(8):1103-11.PMID: 20506141. [Pub Med (http://www.ncbi.nlm.nih.gov/pubmed/20506141) ]

     

  21. Ruperto N, Pistorio A, Ravelli A, Rider LG, Pilkington C, Oliveira S, Wulffraat N, Espada G, Garay S, Cuttica R, Hofer M, Quartier P, Melo-Gomes J, Reed AM, Wierzbowska M, Feldman BM, Harjacek M, Huppertz HI, Nielsen S, Flatø B, Lahdenne P, Michels H, Murray KJ, Punaro L, Rennebohm R, Russo R, Balogh Z, Rooney M, Pachman LM, Wallace C, Hashkes P, Lovell DJ, Giannini EH, Martini A; for Pædiatric Rheumatology International Trials Organisation (PRINTO) the Pediatric Rheumatology Collaborative Study Group (PRCSG), The pediatric rheumatology international trials organization provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis, Arthritis Care Res (Hoboken), 2010 Nov 62(11):1533-41. doi: 10.1002/acr.20280. Epub 2010 Jun 25. [Pub Med]

     

  22. Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE, Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies, Arthritis Care Res (Hoboken), 2010 Apr 62(4):465-72. [Pub Med]

     

  23. Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG, Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008, Neuromuscul Disord, 2010 Feb 20(2):142-7. Epub 2010 Jan 13. [Abstract]

     

  24. Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, Pachman LM, Pilkington C, Reed AM, Rennebohm RM, Rider LG, Wallace CA, Feldman BM, Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference, Arthritis Care Res (Hoboken), 2010 Feb 62(2):219-25.PMID: 20191521. [Pub Med]

     

  25. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, Maillard S, Oliveira SK, Sztajnbok F, Cuttica R, Beltramelli M, Corona F, Katsicas MM, Russo R, Ferriani V, Burgos-Vargas R, Magni-Manzoni S, Solis-Valleoj E, Bandeira M, Zulian F, Baca V, Cortis E, Falcini F, Alessio M, Alpigiani MG, Gerloni V, Saad-Magalhaes C, Podda R, Silva CA, Lepore L, Felici E, Rossi F, Sala E, Martini A, Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients, Arthritis Care Res (Hoboken), 2010 Jan 15 62(1):63-72.PMID: 20191492. [Pub Med]

     

  26. Sanner H, Gran JT, Sjaastad I, Flat� BDivision Rikshospitalet, Medical Faculty, University of Oslo Oslo University Hospital, Rikshospitalet, Oslo, Norway, Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset, Rheumatology (Oxford), 2009 Dec 48(12):1541-7. [Pub Med]

     

  27. Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, Cintas HL, McGarvey CL, James-Newton L, Pokrovnichka A, Moini B, Cabalar I, Lovell DJ, Wesley R, Plotz PH, Miller FW, Hicks JE, Rider LG, Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis, Rheumatology (Oxford), 2009 Feb 48(2):134-9. Epub 2008 Dec 11. [Pub Med]

     

  28. Klein RQ, Bangert CA, Costner M, Connolly MK, Tanikawa A, Okawa J, Rose M, Fakharzadeh SS, Fiorentino D, Lee LA, Sontheimer RD, Taylor L, Troxel AB, Werth VP, Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis, Br J Dermatol, 2008 Sep 159(4):887-94. Epub 2008 Jul 4. [Pub Med]

     

  29. Huber AM, Lachenbruch PA, Dugan EM, Miller FW, Rider LGJuvenile Dermatomyositis Disease Activity Collaborative Study Group, Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats, Arthritis Rheum, 2008 Mar 15 59(3):352-6. [Pub Med]

     

  30. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, Rider LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum.2008 Feb 15;59(2):214-21. [Pub Med]

     

  31. Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, Brunner J, Dannecker G, Silva CA, Stanevicha V, Cate RT, van Suijlekom-Smit LW, Voygioyka O, Fischbach M, Foeldvari I, Hilario O, Modesto C, Saurenmann RK, Sauvain MJ, Scheibel I, Sommelet D, Tambic-Bukovac L, Barcellona R, Brik R, Ehl S, Jovanovic M, Rovensky J, Bagnasco F, Lovell DJ, Martini APaediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG), The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study, Arthritis Rheum, 2008 Jan 15 59(1):4-13. [Pub Med]

     

  32. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, Rider LG; in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group, The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy, Rheumatology (Oxford), 2007 Oct 46(10):1606-11. [Pub Med]

     

  33. Wedderburn LR, Varsani H, Li CK, Newton KR, Amato AA, Banwell B, Bove KE, Corse AM, Emslie-Smith A, Harding B, Hoogendijk J, Lundberg IE, Marie S, Minetti C, Nennesmo I, Rushing EJ, Sewry C, Charman SC, Pilkington CA, Holton JL, UK Juvenile Dermatomyositis Research Group. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials, Arthritis Rheum, 2007 Oct 15 57(7):1192-201. [Pub Med]

     

  34. Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, Domsic R, Ascherman DP, Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy, Arthritis Rheum, 2007 Sep 56(9):3125-31. [Pub Med]

     

  35. Alexanderson H, Broman L, Tollback A, Josefson A, Lundberg IE, Stenstrom CH, Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis, Arthritis Rheum, 2006 Feb 15 55(1):114-22. [Pub Med]

     

  36. Chung YL, Rider LG, Bell JD, Summers RM, Zemel LS, Rennebohm RM, Passo MH, Hicks J, Miller FW, Scott DLJuvenile Dermatomyositis Disease Activity Collaborative Study Group, Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies, Arthritis Rheum, 2005 Aug 15 53(4):565-70. [Pub Med]

     

  37. Ponyi A, Borgulya G, Constantin T, Vancsa A, Gergely L, Danko K, Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis, Rheumatology (Oxford), 2005 Jan 44(1):83-8. Epub 2004 Sep 20. [Pub Med]

     

  38. Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM, Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops, J Rheumatol, 2004 Aug 31(8):1644-9. [Pub Med]

     

  39. Miller FW, Rider LG, Plotz PH, Rutkove SB, Pestronk A, Wortmann RL, Lundberg IE, Argov Z, Isenberg DA, Lacomis D, Oddis CV, Polymyositis: an overdiagnosed entity, Neurology, 2004 Jul 27 63(2):402. [Pub Med]

     

  40. Rennebohm RM, Jones K, Huber AM, Ballinger SH, Bowyer SL, Feldman BM, Hicks J, Katona IM, Lindsley CB, Miller FW, Passo MH, Perez MD, Reed AM, Wallace CA, White PH, Zemel LS, Lachenbruch PA, Hayes JR, Rider LGJuvenile Dermatomyositis Disease Activity Collaborative Study Group, Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale, Arthritis Rheum, 2004 Jun 15 51(3):365-70. [Pub Med]

     

  41. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, Zemel LS, Wallace CA, Ballinger SH, Passo MH, Reed AM, Summers RM, White PH, Katona IM, Miller FW, Lachenbruch PA, Rider LG, Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies, Arthritis Rheum, 2004 May 50(5):1595-603. [Pub Med]

     

  42. Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, Garay S, Kuis W, Machado C, Pachman L, Prieur AM, Rider LG, Silverman E, Tsitsami E, Woo P, Giannini EH, Martini APaediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG), Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis, Rheumatology (Oxford), 2003 Dec 42(12):1452-9. Epub 2003 Jun 27. [Pub Med]

     

  43. Miller FW, Rider LG, Plotz PH, Isenberg DA, Oddis CV, Diagnostic criteria for polymyositis and dermatomyositis, Lancet, 2003 Nov 22 362(9397):1762-3; author reply 1763. [Pub Med]

     

  44. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM, Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence, Arthritis Rheum, 2003 Feb 15 49(1):7-15. [Pub Med]

     

  45. Sultan SM, Ioannou Y, Moss K, Isenberg DA, Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality, Rheumatology (Oxford), 2002 Jan 41(1):22-6. [Pub Med]

     

  46. Rider LG*, AS Schiffenbauer*, M Zito, KL Lim, A Ahmed, LS Zemel, RM Rennebohm, MH Passo, RM Summers, JE Hicks, PA Lachenbruch, MP Heyes, FW Miller, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study GroupJuvenile Dermatomyositis Disease Activity Collaborative Study Group, Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies, Clin. Chem., 2002 Oct 48(10):1681-8; * These authors contributed equally. [Pub Med]

     

  47. Huber A, J.E. Hicks, P.A. Lachenbruch, M.D. Perez, L.S. Zemel, R.M. Rennebohm, C.A. Wallace, C.B. Lindsley, M.H. Passo, S.H. Ballinger, S.L. Bowyer, A.M., P.H. White, I.M. Katona, F.W. Miller, L.G. Rider*, and B.M. Feldman*Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. III. The Childhood Health Assessment Questionnaire (CHAQ), J Rheumatol, 2001 May 28(5):1106-11; * These authors contributed equally. [Pub Med]

     

  48. Lovell D.J., CB. Lindsley, RM. Rennebohm, SH. Ballinger, SL. Bowyer, EH Giannini, JE Hicks, JE Levinson, R. Mier, LM Pachman, MH Passo, MD Perez, AM Reed, KN Schickler, M. Smith, LS Zemel, LG Rider, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group, Development of validated disease activity and disease damage indices for the juvenile idiopathic inflammatory myopathies: II. The Childhood Myositis Assessment Scale: A quantitative tool for the evaluation of muscle function, Arthritis Rheum, 1999 Oct 42(10):2213-9. [Pub Med]

     

  49. Rider, L.G., B.M. Feldman, M.D. Perez, R.M. Rennebohm, C.B. Lindsley, L.S. Zemel, C.A. Wallace, S.H. Ballinger, S.L. Bowyer, A.M. Reed, M.H. Passo, I.M. Katona, F.W. Miller, and P.A. LachenbruchJuvenile Dermatomyositis Disease Activity Collaborative Study Group, Development of Validated Disease Activity and Disease Damage Indices for the Juvenile Idiopathic Inflammatory Myopathies: I. Physician and Parent/Patient Global Assessments, Arthritis Rheum, 1997 Nov 40(11):1976-83. [Pub Med]

Share This Page:

Page Options:

Request Translation Services